Evidence map›Paper›PMID 34724201›Full record

ArticleCancer2022

Prevalence and risk factors of cancer-related fatigue in childhood cancer survivors: A DCCSS LATER study.

Sylvia van Deuren, Adriaan Penson, Eline van Dulmen-den Broeder, Martha A Grootenhuis, Margriet van der Heiden-van der Loo, Ewald Bronkhorst, Nicole M A Blijlevens, Nina Streefkerk, Jop C Teepen, Wim J E Tissing and 10 more

Abstract read
In one paragraph

Article in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Metabolic Implications of Childhood Cancer.Current pediatrics reports · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Sylvia van DeurenRadboudumc Center of Expertise for Cancer Survivorship, Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID 0000-0002-7580-1369
Adriaan PensonRadboudumc Center of Expertise for Cancer Survivorship, Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID 0000-0001-7558-1637
Eline van Dulmen-den BroederDepartment of Pediatric Oncology/Hematology, VU University, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
Martha A GrootenhuisPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Margriet van der Heiden-van der LooDutch Childhood Oncology Group, Utrecht, the Netherlands.
Ewald BronkhorstDepartment for Health Evidence, Biostatistics Section, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
Nicole M A BlijlevensDepartment of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands.
Nina StreefkerkPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Jop C TeepenPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0002-2647-2677
Wim J E TissingPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Helena J H van der PalPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Marry M van den Heuvel-EibrinkPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Birgitta A B VersluysPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Dorine BrestersPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Flora E van LeeuwenDepartment of Epidemiology and Biostatistics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Cécile M RonckersPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Leontien C M KremerPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Hans KnoopDepartment of Medical Psychology, University of Amsterdam, Amsterdam University Medical Centers, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.
Jacqueline J LoonenRadboudumc Center of Expertise for Cancer Survivorship, Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands.
DCCSS-LATER Consortium

Funding

KWF Kankerbestrijding KUN 2014-6985
6 · The paper itself

Abstract

backgroundCancer-related fatigue is a debilitating late effect after treatment for childhood cancer. The prevalence of fatigue in childhood cancer survivors (CCSs) and associated factors for fatigue has varied widely in previous studies. Two important aspects of cancer-related fatigue, its severity and chronicity, are often not assessed. This study investigated the prevalence of, and risk factors for, severe chronic fatigue (CF) in a national cohort of Dutch CCSs.

methodsIn this study, 2810 CCSs (5-year survivors of all childhood malignancies diagnosed between 1963 and 2001 with a current age of 12-65 years) and 1040 sibling controls were included. CF was assessed with the Short Fatigue Questionnaire and was defined as a score ≥ 18 and persistence of fatigue for ≥6 months. Cancer- and treatment-related characteristics, current health problems, and demographic and lifestyle variables were assessed as potential risk factors for CF via multivariable logistic regression analyses.

resultsIn adult CCSs and sibling controls (≥18 years old), the prevalence of CF was 26.1% and 14.1%, respectively (P < .001). In adolescent CCSs and sibling controls (<18 years old), the prevalence of CF was 10.9% and 3.2%, respectively. Female gender (odds ratio [OR], 2.13; 95% confidence interval [CI], 1.73-2.62), unemployment (OR, 2.18; 95% CI, 1.67-2.85), having 1 or more health problems (OR for 1-2, 1.48; 95% CI, 1.18-1.87; OR for >2, 2.20; 95% CI, 1.50-3.21), and a central nervous system diagnosis (OR, 1.74; 95% CI, 1.17-2.60) were significantly associated with CF in adult CCSs.

conclusionsThis study shows that CCSs, regardless of their cancer diagnosis, report CF more often than sibling controls. This study provides new evidence for the prevalence of fatigue in CCSs.

Indexed as

Cancer SurvivorsNeoplasmsAdolescentAdultAgedChildFemaleHumansMiddle AgedPrevalenceRisk FactorsSurvivorsYoung Adultcancer-related fatiguechildhood cancer survivorslate effectssurvivorship

Identifiers

PMID34724201
PMCPMC9298343

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.